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Gingival overgrowth is a serious side effect of 
the administration of cyclosporine. It is worsened 
by bacterial plaque accumulation, and may interfere 
with normal oral functions such as smiling, speaking, 
eating, resulting in psychological problems (1,2). The 
incidence of cyclosporine-induced gingival overgrowth 
(CIGO) is in the range of 20-80% of the patients (3); in 
addition, up to 90% of the transplant recipient patients, 
who have been submitted to cyclosporine therapy, 
present CIGO (4). 
 Several factors such as age, sex, duration 
of treatment and dosage of the prescribed 
cyclosporine are influencing the severity of clinical 
manifestation of CIGO (5-7). Cyclosporine is a 
potent immunosuppressive drug widely prescribed 
for autoimmune diseases therapy, and for treating 
graft versus host disease in organ transplant patients 
(8). To prevent CIGO, several approaches have been 
proposed, such as drug substitution or cyclosporine 
dose reduction, as well as oral hygiene programs and 
surgical interventions, but each of these approaches may 
have contraindications. To prevent CIGO, reducing 
the dosage or using alternative drugs is not possible in 
all situations. Other drugs have their own side effects 
too. However surgical intervention is only proposed 
for cosmetic cases, whilst oral hygiene protocols have 
been demonstrated to be efficient in controlling CIGO 
but could not inhibit its development.
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Gingival overgrowth is a serious side-effect that accompanies the use of cyclosporine. Up to 97% of the patients 
submitted to immunosuppressant drugs have been reported to suffer from this side-effect. Several conflicting 
theories have been proposed to explain the fibroblast’s function in gingival overgrowth. To determine whether 
cyclosporine alter the inflammatory responses, we investigated its effects on gingival fibroblast gene expression 
as compared with untreated cells. Fragments of gingival tissue of healthy volunteers (11-year-old man, 68-year-
old-woman and 20-year-old-man) were collected during operation.  Cells were incubated with cyclosporine and 
gene expression of 29 was investigated in gingival fibroblasts cell culture, compared with untreated cells. The 
gene expression level was significantly deregulated only for 10 genes (CCL1, CCR1, CCR4, CCR5, CCR10, IL1A, 
IL1B, IL5, IL6R and TNFSF10) that were found to be downregulated except for TNFSF10. These results seem to 
demonstrate that cyclosporine has no inflammatory effect on healthy gingival fibroblast. In the future, it would be 
interesting understand, the possible effect of the drug on inflammation of patients affected by gingival hyperplasia.
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alpha (IL1A) and Tumour necrosis factor superfamily 
member 10 (TNFSM10). 
Objective
 To determine whether cyclosporine can alter the 
inflammatory response, we investigated its effects 
on the gene expression of fibroblast isolated from 
healthy volunteers.
MATERIALS AND METHODS
Primary Human Fibroblast cells culture
 Fragments of gingival tissue of healthy volunteers 
(11-year-old man, 68-year-old woman and 20-year-old 
man) were collected during operation. The pieces were 
transferred in 75 cm2 culture flasks containing DMEM 
medium (Sigma Aldrich, Inc., St Louis, Mo, USA) 
supplemented with 20% fetal calf serum, antibiotics 
(Penicillin 100U/ml and Streptomycin 100 micrograms/
ml-Sigma Aldrich, Inc., St Louis, Mo, USA).
 Cells were incubated in a humidified atmosphere of 
5% CO2 at 37°C. The medium was changed the next day 
and twice a week. After 15 days the pieces of gingival 
tissue were removed from the culture flask. Cells were 
harvested after additional 24h of incubation.
Cell viability test
 A stock solution of cyclosporine 1mg/mL was 
prepared. Further dilutions were made with the culture 
medium to the desired concentrations just before use. Cell 
lines were seeded into 96-well plates at a density of 104 
cells per well containing 100µl of cell culture medium and 
incubated for 24h to allow cell adherence. Serial dilution 
of cyclosporine (5000 ng/mL, 2000 ng/mL, 1000 ng/mL, 
500 ng/mL, 100 ng/mL) were added (three wells for each 
concentration). The cell culture medium alone was used 
as negative control.
 After 24h incubation, cell viability was measured using 
PrestoBlue™ Reagent Protocol (Invitrogen) according to 
the manufacturer’s instructions. Briefly, the PrestoBlue™ 
solution (10µl) was added into each well containing 
90µl of treatment solution. Plates were then placed back 
into the incubator for 1h, after which absorbance was 
measured at wavelengths of 570 nm excitation and 620 nm 
emission by an automated microplate reader (Sunrise™, 
Tecan Trading AG). The percentage of viable cells was 
CIGO and Inflammation
 CIGO may produce an inflammation process 
with increased fibrotic response in the extra-cellular 
matrix. Inflammation could be necessary to promote 
the fibrotic process, but not for its progression (9). 
Several studies stated that pathogens bacteria in 
gingival tissue as well as mucous membrane trauma 
may worsen the inflammatory process responsible 
for the severity CIGO (10).
 Immune-inflammatory features associated with 
CIGO show increased macrophage reparative/
proliferative phenotype, up-regulation of essential 
growth factors, IL-1β, and IL-6 cytokines and 
variable lymphocyte proportions (11, 12). Several 
studies have described a lymphocyte infiltration of 
plasma cells in CIGO samples of fibroblasts. This 
would suggest that the humoral immune response 
replaces the cellular immune response in CIGO 
fibroblasts, because of immunosuppressive drugs. 
Moreover, the immunity pattern in patients with 
CIGO is characterized by the low expression of some 
types of lymphocytes (natural killer lymphocytes) in 
contrast to chronic inflammatory periodontal disease. 
The cellular and tissue features of human gingival 
overgrowth lesions caused by phenytoin, nifedipine, 
and cyclosporine, respectively, have different 
histological characteristics: phenytoin provokes low 
inflammation and high fibrosis; nifedipine produces 
more or less inflammation and fibrosis equally, 
whilst cyclosporine produces high inflammation 
and low fibrosis. It is possible that CIGO presents a 
very pronounced activation of immunity system with 
some moderate antifibrotic effects in the synthesis 
and deposition of collagen.
 A positive balance between the synthesis and 
degradation of components of the extracellular 
matrix causes a deposit of the matrix, which has 
been suggested as one of the most significant events 
in CIGO (13). Since the pathogenesis of CIGO is 
not well known, it is supposed that cyclosporine 
influences the regulation of inflammatory mediators 
such as chemokines and cytokines in fibroblast (14). 
Growth factors activity might induce CIGO; in fact, 
some studies show that cyclosporine modifies the 
transcription of several chemokines and cytokines 
such as Chemokine ligand 1 (CCL1), Interleukin 1 
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 cDNA synthesis was performed starting from 500 ng 
of total RNA, using PrimeScript RT Master Mix (Takara 
Bio Inc.). The reaction was incubated at 37°C for 15 min 
and inactivated by heating at 70°C for 10 sec. cDNA 
was amplified by Real Time Quantitative PCR using the 
VIIA™ 7 System (Applied Biosystems).
All PCR reactions were performed in a 20µl volume. 
Each reaction contained 10µL of 2x qPCRBIO SYGreen 
Mix Lo-ROX (Pcrbiosystems), 400nM concentration of 
each primer, and cDNA. 
 Custom primers belonging to the “Inflammatory 
Cytokines and Receptors” pathway were purchased from 
Sigma Aldrich. All experiments were performed including 
non-template controls to exclude reagents contamination. 
PCR was performed including two analytical replicates. 
 The amplification profile was initiated by 10 min 
incubation at 95°C, followed by two-step amplification of 
15 sec at 95°C and 60 sec at 60°C for 40 cycles. As a final 
step, a melt curve dissociation analysis was performed. 
Statistical analysis
 The gene expression levels were normalized to the 
expression of the reference gene (RPL13) and were 
expressed as fold changes relative to the expression of the 
determined by comparing the average absorbance in drug 
treated wells with average absorbance in control wells 
exposed to vehicle alone. The results were presented as 
the mean ± standard deviation of three measures.
Cell treatment
 Cell lines were seeded at a density of 1.0 x 105 cells/ml 
into 9cm2 (3ml) wells and subjected to serum starvation 
for 16 h at 37°C. Cells were treated with 1000 ng/mL 
cyclosporine solution for 24h. This solution was obtained 
in DMEM supplemented with 2% FBS, antibiotics and 
aminoacids. Cell medium alone was used as negative 
control. The cells were maintained in a humidified 
atmosphere of 5% CO2 at 37°C. After the end of the 
exposure time cells were trypsinized and processed for 
RNA extraction.
RNA isolation, reverse transcription and quantitative 
real-time RT-PCR
 Total RNA was isolated from cell lines using GenElute 
mammalian total RNA purification miniprep kit (Sigma-
Aldrich) according to manufacturer’s instructions. Pure 
RNA was quantified at NanoDrop 2000 spectrophotometer 
(Thermo Scientific).
 
Fig. 1. Amplification plot curves of the 29 genes belonging to the “Inflammatory Cytokines and Receptors” pathway 
analyzed using Real time PCR.
24 (S1)
concentration, about 80% of cells were vital.
 After the treatment the gene expression levels of 
29 genes belonging to the “Inflammatory Cytokines 
and Receptors” pathway was studied. The gene name 
and their fold change measured by Real Time PCR 
are reported in Table I. Fig. 1 shows the amplification 
plot profile of the amplifications.
 Bold fonts indicate significant variation of gene 
expression level: fold change ≥ 2 and p value ≤ 0.05 
for up-regulated genes, and fold change ≤ 0.5 and p 
value ≤ 0.05 for significantly down-regulated genes. 
Table II shows the 10 genes whose expression was 
significantly deregulated.
All genes (CCL1, CCR1, CCR4, CCR5, CCR10, 
IL1A, IL1B, IL5, IL6R) were downregulated except 
TNFSF10 (Table I, Fig. 2)
DISCUSSION
 CIGO is a pathological expression of the 
consequences of the assault from both mechanical 
stimuli and side effects of drugs on the oral mucosa. 
Gingival mucosa has been developed biological 
mechanism to combat these noxious stimuli, and 
in this process, cells of the innate immune system 
play a major role. CIGO is the response of molecular 
regulatory pathways that coordinate the host 
response to the effect of drug administration and 
other microbiological patterns. Innate immunity 
also plays a fundamental role in the pathogenesis of 
CIGO, since it acts as a surveillance mechanism to 
prevent chronic inflammation. In addiction chronic 
inflammation is now recognized as a starting 
mechanism of tumour development. It is thought 
that upregulated inflammation within the cellular 
microenvironment, is one of the key elements causing 
CIGO, however, how immune and inflammatory 
processes are regulated and how they may result in 
different clinical manifestations are initial questions 
that are beginning to be understood in some detail.
 CIGO and its chronic inflammation are sustained 
by oral biofilm including bacteria, viruses and fungi, 
living in a homeostatic balance with each other and 
the immunity system (13). The dysbiosis causing 
CIGO, and the unbalance between oral bacteria 
and host pro-inflammatory and anti-inflammatory 
untreated cells. Quantification was done with the delta/
delta Ct calculation method (15). 
RESULTS
 The cell viability test PrestoBlue™ established 
that the optimal concentration of cyclosporine to 
carry out the treatment was 1000 ng/ml. At this 
Gene Fold change Gene function 
CCL1 0,24 Chemokine 
CCL2 0,89 Chemokine 
CCL2D 0,80 Chemokine 
CCL5 0,92 Chemokine 
CCL8 0,59 Chemokine 
CXCL5 0,82 Chemokine 
CXCL10 0,70 Chemokine 
CCR1 0,10 Chemokine receptor 
CCR4 0,12 Chemokine receptor 
CCR5 0,15 Chemokine receptor 
CCR6 1,30 Chemokine receptor 
CCR10 0,46 Chemokine receptor 
CXCR5 0,82 Chemokine receptor 
IL1A 0,30 Interleukin 
IL1B 0,28 Interleukin 
IL5 0,10 Interleukin 
IL6 0,73 Interleukin 
IL7 0,65 Interleukin 
IL8 0,72 Interleukin 
ILR1 0,70 Interleukin receptor 
IL1RN 0,65 Interleukin receptor 
IL6R 0,13 Interleukin receptor 
IL10RB 1,04 Interleukin receptor 
BMP2 1,76 Cytokine 
SPP1 1,46 Cytokine 
TNFRSF 0,96 Cytokine 
TNFSF10 9,39 Cytokine 
VEGFA 1,43 Cytokine 
RPL13 1,00 Housekeeping genes  
 
Table I. Selected genes used in Real Time PCR belonging 
to “Inflammatory Cytokines and Receptors” pathway. In 
bold the Fold change of significant gene expression level.
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 Disease progression in CIGO is a complex 
process that involves the interaction of multiple 
components of the host immune response and the 
oral microbiome. Chemokines and cytokines with 
their receptors releasing inflammatory mediators 
play a central role in CIGO development, however, 
the deregulated tissue homeostasis and inflammation 
process in CIGO, exposes oral mucosa to the product 
of altered metabolism such as necrotic cells, reactive 
mediators, are factors influencing the severity of 
CIGO. Weakened immune system as the result 
from administration of antisuppresant drugs such 
as cyclosporine, allows increased dysbiotic oral 
microflora sustaining the etiopathogenesis of CIGO 
(14). Although it is known that microbial dysbiosis 
promotes CIGO, deregulated immune response 
mechanisms determine the progression and the 
extent of tissue overgrowth.
 
Gene Fold change SD (+/-) Gene function 
CCL1 0,24 0,03 Chemokine 
CCR1 0,10 0,01 Chemokine receptor 
CCR4 0,12 0,02 Chemokine receptor 
CCR5 0,15 0,00 Chemokine receptor 
CCR10 0,46 0,05 Chemokine receptor 
IL1A 0,30 0,01 Interleukin 
IL1B 0,28 0,04 Interleukin 
IL5 0,10 0,02 Interleukin 
IL6R 0,13 0,00 Interleukin receptor 
TNFSF10 9,39 0,27 Cytokine 
 
Fig. 2. Gene expression profile of fibroblast treated with cyclosporine 1000 ng/mL.
Table II. Significant gene expression levels after 24h treatment with cyclosporine, as compared with untreated cells.
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oxygen, free radicals, etc. These host-derived factors 
may likely alter cells and promote production of 
more inflammatory mediators, further enhancing 
inflammation and contributing to CIGO pathogenesis 
(16).
Chemokine and cytokine
 The gingival mucosa is constantly subjected 
to thermic, chemical, mechanical insults inducing 
a permanent state of turnover, involving the 
inflammatory cells, fibroblasts and inflammatory 
mediators. Many of these mediators are chemokine 
and cytokines secreted locally by various cells in the 
gingiva.
 In this study, gingival fibroblasts of healthy 
individuals were treated for 24 h with 1000 ng/
ml of cyclosporine. Gene expression analysis 
showed that only 10 of the analyzed genes were 
significantly deregulated. Among these there are the 
chemokine CCL1, CCR1, CCR4, CCR5, CCR10 
and the interleukine IL1A, IL1B, IL5, IL6R. All 
the mentioned genes were down-regulated.  The 
only gene strongly over-expressed was TNFSF10 a 
cytokine that belongs to the tumor necrosis factor 
(TNF) ligand family. This protein preferentially 
induces apoptosis in transformed and tumor cells 
but does not appear to kill normal cells although it 
is expressed at a significant level in most normal 
tissues (17-29).
 In this study, all the significantly deregulated 
genes belonging to the “Inflammatory Cytokines and 
Receptors” pathway were downregulated, except 
TNFSF10.  
These results seem to indicate that cyclosporine 
has no effect on the modulation of inflammatory 
response in gingival fibroblasts.
 Probably more explanatory results could be 
obtained by using fibroblasts isolated from patients 
affected by gingival hyperplasia in wich the use of 
cyclosporine seems to aggravate the inflammatory 
response and the gingival overgrowth
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